BioAlliance Pharma: 2008 Consolidated Turnover: +134%

Regulatory News:

BioAlliance Pharma SA (Euronext Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a 2008 turnover of €8.2 million, strongly increased from €3.5 million in 2007.

Over the course of 2008, the company pro-actively pursued its international licensing and partnering strategy, notably via the signature of two agreements with companies in south-east Asia. BioAlliance Pharma has now signed Loramyc® licensing agreements for a total of up to €90 million, with €25 million in cash already received over the period 2007-2008. Licensing and partnering revenues for 2008 amounted to €7 million and can be broken down as follows:

• a licensing agreement in the United States (with Par Pharmaceutical): €4.1 million.
• licensing agreements in Europe (with SpePharm) and south-east Asia (with Handok and NovaMed): €2.9 million.

Loramyc® sales continue to grow strongly and are in line with forecasts, with a consolidated turnover of €1 million for the product's first full year commercialization, 96% of which generated in France.

Since Loramyc®'s launch in September 2007, almost 19,000 patients have been treated with the compound in France - well over the target of 16,000 set in August 2008. This result has been achieved thanks to support from opinion leaders, coherence with official guidelines and the work performed by BioAlliance Pharma in the field of oropharyngeal candidiasis.

Available cash and cash equivalents as of December 31, 2008, amounted to €31.7 million. The company expects early reimbursement of its research tax credit estimated at over €4 million. Furthermore, without taking into account any future agreement, BioAlliance Pharma forecasts to receive US$ 21.5 million in milestone payments in 2009-2010 from existing partners.

"We are delighted with Loramyc®'s success among the medical community in the oncology supportive care segment, in which we are becoming a partner of choice. We are confident that sales will continue to grow", stated Dominique Costantini, BioAlliance Pharma's President and CEO. "Our solid cash position means we can plan to pursue our commercial development with confidence, while forging additional industrial alliances on portfolio products".

BioAlliance Pharma COO Pierre Morgon added: "Following the successful launch of Loramyc® in France, BioAlliance Pharma is positioning itself as a key partner for hospital-based specialist physicians treating opportunistic infections in cancer and AIDS patients. We are going to reinforce our portfolio of marketed products, thanks to the two novel formulations of ondansetron (used in post-chemo/radiotherapy supportive care) that we have in-licensed for Europe in 2008".

Conference call on Tuesday February 10, 2009
From 6:45 pm to 7:30 pm (CET / Paris time) in English

• from France, please dial: 0805 11 86 18
• from the US, please dial: 0808 238 6089
• from the UK, please dial: 0800 279 9127 and pin code : 848736#
• from Belgium, please dial: 0800 483 70 and pin code : 848736#
• from Germany please dial: 0800 1014 772 and pin code : 848736#
• from Switzerland please dial: 080 000 0244 and pin code : 848736#

The conference call replay will be available to listen after 7.30 pm today
by dialing + 33 (0)1 72 00 14 59, then dial the pin code 24 21 06#

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health and quality of life. BioAlliance Pharma’s ambition is to become a leading European player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).